Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 8/20 | 0.50 |
| ▸ | LPL | P06858 | 7/20 | 0.50 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | KMO | O15229 | 1/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.32 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794354 | 0.94 | DGAT1 (0.53) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL21390496 | 0.91 | DGAT1 (0.43) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL19834881 | 0.89 | DGAT1 (0.45) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL19933637 | 0.88 | LIPG (0.56) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL20696492 | 0.87 | DGAT1 (0.47) | LIPGLPLDGAT1PDGFRBKDR | |
| SCHEMBL29412555 | 0.86 | LIPG (0.56) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL22660881 | 0.86 | LIPG (0.56) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL19933647 | 0.85 | DGAT1 (0.43) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL19933611 | 0.85 | DGAT1 (0.43) | LIPGLPLDGAT1HSD17B1HSD17B2 | |
| SCHEMBL18015663 | 0.85 | DGAT1 (0.59) | LIPGLPLDGAT1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-11917903-B2 | Metal complexes | UDC IRELAND LIMITED (IE) | 2024-02-27 | — | — | US | disclosed |
| US-20210111345-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2021-04-15 | — | — | US | disclosed |
| WO-2019179909-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111345-A1 | METAL COMPLEXES | NCLN, BICRA, AP3M1 | LIPG 3983/4885LPL 3716/4885DGAT1 2190/4885 |
| US-11917903-B2 | Metal complexes | NCLN, BICRA, AP3M1 | LIPG 3983/4885LPL 3716/4885DGAT1 2190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.